Evidence map›Paper›PMID 26896392›Full record

ArticleNeural development2016

Evx1 and Evx2 specify excitatory neurotransmitter fates and suppress inhibitory fates through a Pax2-independent mechanism.

José L Juárez-Morales, Claus J Schulte, Sofia A Pezoa, Grace K Vallejo, William C Hilinski, Samantha J England, Sarah de Jager, Katharine E Lewis

Open access · goldAbstract read
In one paragraph

Article in Neural development, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. iScience · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

José L Juárez-MoralesDepartment of Biology, Syracuse University, 107 College Place, Syracuse, NY, 13244, USA.
Claus J SchulteDepartment of Physiology, Development and Neuroscience, University of Cambridge, Downing Street, Cambridge, CB2 3DY, UK.
Sofia A PezoaDepartment of Biology, Syracuse University, 107 College Place, Syracuse, NY, 13244, USA.
Grace K VallejoDepartment of Biology, Syracuse University, 107 College Place, Syracuse, NY, 13244, USA.
William C HilinskiDepartment of Biology, Syracuse University, 107 College Place, Syracuse, NY, 13244, USA.
Samantha J EnglandDepartment of Biology, Syracuse University, 107 College Place, Syracuse, NY, 13244, USA.
Sarah de JagerDepartment of Physiology, Development and Neuroscience, University of Cambridge, Downing Street, Cambridge, CB2 3DY, UK.
Katharine E LewisDepartment of Biology, Syracuse University, 107 College Place, Syracuse, NY, 13244, USA. kelewi02@syr.edu.
Syracuse University · USUniversity of Cambridge · GBSUNY Upstate Medical University · US

Funding

Specification of Functional Characteristics of Spinal Cord InterneuronsR01NS077947 · NINDS · SYRACUSE UNIVERSITY · PI LEWIS, KATHARINE EMMA · 2014 to 2019
$1.6M
Identifying transcription factors expressed by ventral spinal cord interneuronsR21NS073979 · NINDS · SYRACUSE UNIVERSITY · PI LEWIS, KATHARINE EMMA · 2011 to 2013
$454k
NINDS NIH HHS R01 NS077947NINDS NIH HHS R21 NS073979NINDS NIH HHS R21NS073979Wellcome Trust
6 · The paper itself

Abstract

backgroundFor neurons to function correctly in neuronal circuitry they must utilize appropriate neurotransmitters. However, even though neurotransmitter specificity is one of the most important and defining properties of a neuron we still do not fully understand how neurotransmitter fates are specified during development. Most neuronal properties are determined by the transcription factors that neurons express as they start to differentiate. While we know a few transcription factors that specify the neurotransmitter fates of particular neurons, there are still many spinal neurons for which the transcription factors specifying this critical phenotype are unknown. Strikingly, all of the transcription factors that have been identified so far as specifying inhibitory fates in the spinal cord act through Pax2. Even Tlx1 and Tlx3, which specify the excitatory fates of dI3 and dI5 spinal neurons work at least in part by down-regulating Pax2.

methodsIn this paper we use single and double mutant zebrafish embryos to identify the spinal cord functions of Evx1 and Evx2.

resultsWe demonstrate that Evx1 and Evx2 are expressed by spinal cord V0v cells and we show that these cells develop into excitatory (glutamatergic) Commissural Ascending (CoSA) interneurons. In the absence of both Evx1 and Evx2, V0v cells still form and develop a CoSA morphology. However, they lose their excitatory fate and instead express markers of a glycinergic fate. Interestingly, they do not express Pax2, suggesting that they are acquiring their inhibitory fate through a novel Pax2-independent mechanism.

conclusionsEvx1 and Evx2 are required, partially redundantly, for spinal cord V0v cells to become excitatory (glutamatergic) interneurons. These results significantly increase our understanding of the mechanisms of neuronal specification and the genetic networks involved in these processes.

Indexed as

AnimalsGABAergic NeuronsGlutamic AcidGlycineHomeodomain ProteinsInterneuronsPAX2 Transcription FactorSpinal CordZebrafishZebrafish Proteinsevx1 protein, zebrafishEvx2 protein, zebrafishGlutamic AcidGlycineHomeodomain Proteinspax2a protein, zebrafishPAX2 Transcription FactorZebrafish Proteins

Identifiers

PMID26896392
PMCPMC4759709
OpenAlexW2279238409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.